

Health Advisory

COVID-19 Therapeutics: Monoclonal Antibodies Update April 14, 2022

SUMMARY POINTS

- Sotrovimab has limited effectiveness against Omicron BA.2.
- CDC confirmed that the Omicron BA.2 variant accounts for more than 85% of all COVID in the US
- FDA no longer authorizes Sotrovimab to treat COVID-19 in any U.S. region due to increased proportions of Omicron BA.2 sub-variant.
- Other COVID-19 treatment options are available, including Paxlovid (Nirmatrelvir/Ritonavir), Veklury (Remdesivir), Lagevrio (Molnupiravir), and Bebtelovimab.
- COVID-19 vaccination continues to support protection against severe illness, hospitalization, and death.

As of April 9th, the Centers for Disease Control and Prevention (CDC) stated that the proportion of BA.2 in the United States is 85.9%. Research has demonstrated decreased effectiveness of Sotrovimab against Omicron BA.2.

Beginning April 5th, 2022, the U.S. Food & Drug Administration (FDA) no longer authorizes Sotrovimab to treat COVID-19 in any U.S. region due to the increased variant proportion of Omicron BA.2. Therefore, the distribution of Sotrovimab has paused in all the U.S. Department of Health and Human Services (HHS) regions on the same day.

The updated National Institutes of Health (NIH) treatment guidelines for non hospitalized patients are as follows:

- The preferred therapies are Paxlovid (Ritonavir-boosted Nirmatrelvir) and Remdesivir.
- If neither of the preferred therapies is available, feasible to use, or clinically appropriate, Bebtelovimab and Molnupiravir are available.

The federal government has launched the [COVID-19 test to treat locator](#) which can help patients find locations where they can be both tested and prescribed oral antivirals.

Ongoing research continues to support vaccination to increase protection against severe COVID-19 illness, hospitalization, and death. Healthcare professionals should continue to strongly encourage their patients to receive the COVID-19 vaccines if they are not up to date.

Resources:

- [COVID-19 Test to Treat Locator](#)
- [Distribution of Sotrovimab Paused to All HHS Regions](#)
- [FDA updates Sotrovimab emergency use authorization](#)
- [NIH: What's New in the Guidelines](#)
- [PA HAN Therapeutics to Prevent and Treat COVID-19](#)